2015 trends in the pharmaceutical industry

As one of the country’s major pharmaceutical industry recruiters, Key Corporate Services follows the trends in that industry closely.  A recent article in Chemical & Engineering News highlighted some very positive 2015 trends in the pharma sector. The most significant patterns centered on drug approvals and megadeals involving mergers.

Overall, the year ends on a positive note for the pharma industry, according to the C&EN package. Drug sales grew about 5 percent to $958 billion, and the Food and Drug Administration had approved 40 novel therapeutics — several of them for cancer treatments that harness the immune system — by early December. That’s just one short of last year’s two-decade peak.

Acquisitions by heavyweights such as Roche and Valeant Pharmaceuticals don’t yet beat the deals of the preceding year, but a pending $160 billion purchase of an Irish specialty drug firm by Pfizer could change that.

While the industry has much to celebrate, not all news in 2015 was rosy. The market’s appetite for biotech diminished this summer although established and nascent hubs are growing.  Conversely, the new genome-editing technique known as CRISPR/Cas9 or simply CRISPR has spurred a boom in gene-therapy research.

If you currently work in pharma and are considering a change, give Key Corporate Services a call.  We have several openings. Many are for business Development professionals to sell their services to the Pharma/Biotech market.

From The Key Corporate Services Blog Team